Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase 1/2 2

Status

Withdrawn 1Terminated 1Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Colorectal Neoplasms 3Squamous Cell Carcinoma of Head and Neck 1Glioma 1Glioblastoma 1Carcinoma 1

Interventions

Bevacizumab 234Fluorouracil 220Oxaliplatin 216Irinotecan 215Leucovorin 199Capecitabine 153Cetuximab 146Panitumumab 70Folfox protocol 51regorafenib 43Radiotherapy 38pembrolizumab 37IFL protocol 36HMPL-013 36trifluridine tipiracil drug combination 32Nivolumab 32Drug Therapy 26Neoadjuvant Therapy 24Trifluridine 18Celecoxib 18tislelizumab 17XELOX 17sintilimab 16Trastuzumab 16durvalumab 15atezolizumab 15aflibercept 15Chemotherapy, Adjuvant 15Biopsy 15apatinib 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Colorectal Neoplasms × futuximab × Clear all
NCT03549338 2020-09-28

Sym004 Versus Futuximab or Modotuximab in Patients With mCRC

Symphogen A/S

Phase 2 Terminated
2 enrolled 9 charts
Gastrointestinal

Carcinoma, Colorectal Neoplasms

NCT02083653 2019-04-16

Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer

Symphogen A/S

Phase 2 Completed
254 enrolled 21 charts
Gastrointestinal

Colorectal Neoplasms

NCT02965417 2017-02-01

Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients

Symphogen A/S

Phase 2 Withdrawn
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡